We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Teleflex (TFX) Q2 Earnings
Read MoreHide Full Article
Analysts on Wall Street project that Teleflex (TFX - Free Report) will announce quarterly earnings of $3.33 per share in its forthcoming report, representing a decline of 2.4% year over year. Revenues are projected to reach $763.39 million, increasing 2.7% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
In light of this perspective, let's dive into the average estimates of certain Teleflex metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net Revenues- Interventional' of $137.89 million. The estimate suggests a change of +10.5% year over year.
According to the collective judgment of analysts, 'Net Revenues- Interventional Urology' should come in at $83.48 million. The estimate indicates a change of +7.3% from the prior-year quarter.
The average prediction of analysts places 'Revenues- OEM (Original Equipment Manufacturer and Development Services)' at $88.27 million. The estimate suggests a change of +5% year over year.
It is projected by analysts that the 'Net Revenues- Vascular Access' will reach $181.31 million. The estimate indicates a year-over-year change of +4.3%.
Analysts' assessment points toward 'Net Revenues- Anesthesia' reaching $104.01 million. The estimate points to a change of +3.2% from the year-ago quarter.
Analysts forecast 'Net Revenues- Other' to reach $55.13 million. The estimate suggests a change of -27.5% year over year.
The consensus among analysts is that 'Net Revenues- Surgical' will reach $111.50 million. The estimate indicates a change of +5.2% from the prior-year quarter.
The combined assessment of analysts suggests that 'Geographic Revenues- Americas' will likely reach $432.19 million. The estimate suggests a change of +1.8% year over year.
Analysts predict that the 'Geographic Revenues- Asia' will reach $87.90 million. The estimate points to a change of +1.4% from the year-ago quarter.
Analysts expect 'Geographic Revenues- EMEA' to come in at $157.16 million. The estimate points to a change of +6.3% from the year-ago quarter.
Shares of Teleflex have experienced a change of +5.4% in the past month compared to the -0.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TFX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Teleflex (TFX) Q2 Earnings
Analysts on Wall Street project that Teleflex (TFX - Free Report) will announce quarterly earnings of $3.33 per share in its forthcoming report, representing a decline of 2.4% year over year. Revenues are projected to reach $763.39 million, increasing 2.7% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
In light of this perspective, let's dive into the average estimates of certain Teleflex metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net Revenues- Interventional' of $137.89 million. The estimate suggests a change of +10.5% year over year.
According to the collective judgment of analysts, 'Net Revenues- Interventional Urology' should come in at $83.48 million. The estimate indicates a change of +7.3% from the prior-year quarter.
The average prediction of analysts places 'Revenues- OEM (Original Equipment Manufacturer and Development Services)' at $88.27 million. The estimate suggests a change of +5% year over year.
It is projected by analysts that the 'Net Revenues- Vascular Access' will reach $181.31 million. The estimate indicates a year-over-year change of +4.3%.
Analysts' assessment points toward 'Net Revenues- Anesthesia' reaching $104.01 million. The estimate points to a change of +3.2% from the year-ago quarter.
Analysts forecast 'Net Revenues- Other' to reach $55.13 million. The estimate suggests a change of -27.5% year over year.
The consensus among analysts is that 'Net Revenues- Surgical' will reach $111.50 million. The estimate indicates a change of +5.2% from the prior-year quarter.
The combined assessment of analysts suggests that 'Geographic Revenues- Americas' will likely reach $432.19 million. The estimate suggests a change of +1.8% year over year.
Analysts predict that the 'Geographic Revenues- Asia' will reach $87.90 million. The estimate points to a change of +1.4% from the year-ago quarter.
Analysts expect 'Geographic Revenues- EMEA' to come in at $157.16 million. The estimate points to a change of +6.3% from the year-ago quarter.
View all Key Company Metrics for Teleflex here>>>
Shares of Teleflex have experienced a change of +5.4% in the past month compared to the -0.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TFX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>